Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NYSE:BHVN NASDAQ:DNTH NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.65+0.8%$5.42$3.96▼$9.85$2.44B0.412.61 million shs2.27 million shsBHVNBiohaven$15.05+3.9%$16.11$13.75▼$55.70$1.48B0.911.30 million shs1.61 million shsDNTHDianthus Therapeutics$20.61-2.3%$18.68$13.37▼$32.27$678.25M1.38269,662 shs645,307 shsVCELVericel$41.23-0.7%$41.85$37.39▼$63.00$2.09B1.32421,598 shs562,781 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+0.83%-4.37%+30.68%+53.64%-9.28%BHVNBiohaven+4.15%+2.87%-10.29%-14.25%-58.40%DNTHDianthus Therapeutics-2.28%+7.82%+9.92%+17.04%-28.04%VCELVericel-0.65%-1.33%-9.78%-0.05%-9.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Cos3.6927 of 5 stars1.93.00.04.02.33.30.6BHVNBiohaven3.1821 of 5 stars4.51.00.00.01.82.50.6DNTHDianthus Therapeutics1.5707 of 5 stars3.60.00.00.03.30.80.0VCELVericel2.9479 of 5 stars3.51.00.00.03.30.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.83Reduce$7.309.86% UpsideBHVNBiohaven 3.07Buy$58.46288.45% UpsideDNTHDianthus Therapeutics 3.13Buy$53.00157.16% UpsideVCELVericel 3.00Buy$61.1448.30% UpsideCurrent Analyst Ratings BreakdownLatest DNTH, VCEL, BHC, and BHVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025DNTHDianthus TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform6/18/2025BHVNBiohavenJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$68.00 ➝ $55.006/16/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.005/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/19/2025BHVNBiohavenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$54.00 ➝ $21.005/13/2025BHVNBiohavenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025BHVNBiohavenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$61.00 ➝ $54.005/13/2025DNTHDianthus TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$58.00 ➝ $50.005/13/2025DNTHDianthus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.005/2/2025BHCBausch Health CosRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/28/2025BHVNBiohavenRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $57.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.26$7.82 per share0.85($0.89) per share-7.47BHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/ADNTHDianthus Therapeutics$6.24M106.22N/AN/A$11.91 per share1.73VCELVericel$238.54M8.70$0.31 per share132.80$5.92 per share6.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M-$0.11N/A1.43N/A-0.41%-540.45%5.26%7/30/2025 (Estimated)BHVNBiohaven-$846.42M-$9.36N/AN/AN/AN/A-257.07%-164.01%8/5/2025 (Estimated)DNTHDianthus Therapeutics-$84.97M-$2.88N/AN/AN/A-1,544.23%-29.26%-27.87%8/6/2025 (Estimated)VCELVericel$10.36M$0.031,374.7993.70N/A1.25%1.09%0.73%7/30/2025 (Estimated)Latest DNTH, VCEL, BHC, and BHVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025VCELVericel-$0.04N/AN/AN/A$64.61 millionN/A7/30/2025Q2 2025BHCBausch Health Cos$0.9320N/AN/AN/A$2.47 billionN/A5/12/2025Q1 2025BHVNBiohaven-$1.67-$2.17-$0.50-$2.17$1.25 millionN/A5/12/2025Q1 2025DNTHDianthus Therapeutics-$0.86-$0.82+$0.04-$0.82$0.81 million$1.16 million5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/ADNTHDianthus TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CosN/A1.350.97BHVNBiohavenN/A2.332.33DNTHDianthus TherapeuticsN/A15.9815.99VCELVericelN/A5.014.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%BHVNBiohaven88.78%DNTHDianthus Therapeutics47.53%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipBHCBausch Health Cos8.05%BHVNBiohaven16.00%DNTHDianthus Therapeutics8.15%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.08 million340.29 millionOptionableBHVNBiohaven239102.11 million85.78 millionOptionableDNTHDianthus Therapeutics8032.16 million29.54 millionOptionableVCELVericel30050.34 million47.73 millionOptionableDNTH, VCEL, BHC, and BHVN HeadlinesRecent News About These CompaniesVericel Corporation (NASDAQ:VCEL) Receives $61.14 Average Price Target from AnalystsJuly 5, 2025 | americanbankingnews.comAllspring Global Investments Holdings LLC Sells 11,632 Shares of Vericel Corporation (NASDAQ:VCEL)July 4, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Buy" from BrokeragesJuly 2, 2025 | marketbeat.comLisanti Capital Growth LLC Acquires 13,585 Shares of Vericel Corporation (NASDAQ:VCEL)June 29, 2025 | marketbeat.comIf EPS Growth Is Important To You, Vericel (NASDAQ:VCEL) Presents An OpportunityJune 20, 2025 | finance.yahoo.comConestoga Capital Advisors LLC Sells 7,830 Shares of Vericel Co. (NASDAQ:VCEL)June 17, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Shares Down 3.8% - What's Next?June 16, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Receives "Overweight" Rating from StephensJune 16, 2025 | marketbeat.comVericel Corporation: Moving From Sell To NeutralJune 12, 2025 | seekingalpha.comVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 11, 2025 | morningstar.comMVericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025June 10, 2025 | globenewswire.com5VCEL : What Analysts Are Saying About Vericel StockMay 23, 2025 | benzinga.comVericel at BofA Securities Conference: Growth and Innovation in HealthcareMay 16, 2025 | investing.comWhich Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?May 10, 2025 | aaii.comAVericel Corporation: Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability GuidanceMay 9, 2025 | finanznachrichten.deVericel Corp (VCEL) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...May 9, 2025 | finance.yahoo.comVericel Corporation 2025 Q1 - Results - Earnings Call PresentationMay 8, 2025 | seekingalpha.comVericel Corporation (VCEL) Q1 2025 Earnings Conference Call TranscriptMay 8, 2025 | seekingalpha.comVericel Corporation (VCEL) Reports Q1 Loss, Misses Revenue EstimatesMay 8, 2025 | zacks.comVericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability GuidanceMay 8, 2025 | globenewswire.comVericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025May 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNTH, VCEL, BHC, and BHVN Company DescriptionsBausch Health Cos NYSE:BHC$6.64 +0.06 (+0.83%) Closing price 07/10/2025 03:59 PM EasternExtended Trading$6.59 -0.06 (-0.89%) As of 07/10/2025 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Biohaven NYSE:BHVN$15.05 +0.57 (+3.94%) Closing price 07/10/2025 03:59 PM EasternExtended Trading$15.02 -0.03 (-0.20%) As of 05:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Dianthus Therapeutics NASDAQ:DNTH$20.61 -0.48 (-2.28%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$21.00 +0.39 (+1.89%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Vericel NASDAQ:VCEL$41.23 -0.27 (-0.65%) Closing price 07/10/2025 04:00 PM EasternExtended Trading$41.23 0.00 (0.00%) As of 07/10/2025 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
